Innovative approaches to treat steroid-resistant or steroid refractory GVHD

Bone Marrow Transplant. 2008 Oct:42 Suppl 2:S101-5. doi: 10.1038/bmt.2008.294.

Abstract

First-line treatment of GVHD is based on steroids and produces sustained responses in 50-80% of patients with acute GVHD (aGVHD) and 40-50% of patients with chronic GVHD (cGVHD) depending on the initial disease severity. Non-responding children are offered second-line therapy with combinations of various agents, but currently available agents have not improved survival in these high-risk populations. In this minireview, we will focus on new agents to treat GVHD in paediatric patients.

Publication types

  • Review

MeSH terms

  • Acute Disease
  • Child
  • Child, Preschool
  • Chronic Disease
  • Disease-Free Survival
  • Drug Resistance*
  • Female
  • Graft vs Host Disease / mortality
  • Graft vs Host Disease / therapy*
  • Humans
  • Immunotherapy / methods*
  • Male
  • Steroids*

Substances

  • Steroids